Amgen Walks Away From TScan as Amylyx Lines Up $350M

Amgen is terminating its partnership with Waltham, Massachusetts-based T cell therapy developer TScan Therapeutics, while Amylyx disclosed a $350 million offering; TCRX traded 5.91% lower at 0.78 and AMLX rose 9.00% to 38.27 as of 17:41 GMT on Aug. 19, 2026.

Two very different signals landed in the same news cycle on Wednesday. Amgen (AMGN) is walking away from its research partnership with TScan Therapeutics (TCRX), the Waltham, Massachusetts-based T cell therapy developer, which disclosed the termination itself. Separately, Amylyx (AMLX) unveiled a $350 million offering — a raise large enough to reset the company's balance sheet, and one the market greeted warmly rather than punishing.

The pairing is instructive. In a sector where partner money and public-market money are the only two reliable sources of runway, one company just lost access to the first while another leaned hard on the second, and shareholders reacted in opposite directions on the same afternoon.

What the termination takes away from TScan

TScan builds T cell receptor-engineered therapies — treatments that arm a patient's immune cells with receptors designed to recognize specific tumor targets. That work is capital-intensive and long-dated, which is precisely why partnerships with large-cap pharma matter so much to companies at TScan's scale. A big-pharma collaboration supplies three things at once: cash that is not dilutive, external validation of the platform, and an implicit option on a future commercial partner.

Ending the Amgen alliance removes all three at the same time. The specific economics of the collaboration — what was paid up front, what remained in milestone payments, what research funding was still flowing — were not detailed in the disclosure covered by Endpoints News, and investors will want that arithmetic quickly. Until it arrives, the market is left pricing an unquantified hole in the funding plan.

The share reaction reflected that uncertainty rather than panic. TCRX changed hands at 0.78, down 5.91% from a prior close of 0.82, with a day range of 0.77 to 0.82, according to licensed intraday market data as of 17:41 GMT on Aug. 19, 2026. A sub-dollar quote is its own piece of information: it tells you the equity market was already assigning limited value to the pipeline before the news, and it narrows the practical financing options available now.

Amgen, for its part, is a company for which a single discovery-stage collaboration is a rounding error. AMGN traded at 438.43, up 3.09% on the day from a prior close of 425.28, inside a range of 429.38 to 441.98. The stock rose on a day when the broader tape was mixed — the S&P 500 proxy SPY was up 0.25% at $769.37, the Dow proxy DIA up 0.22% at $534.10, while the Nasdaq 100 proxy QQQ slipped 0.18% to $716.23. Nothing in that move can be attributed to the TScan decision; large pharmas prune external research commitments routinely, and the market treats such prunings as housekeeping.

The dilution question behind Amylyx's $350 million

Amylyx's disclosure runs the other way. A $350 million offering is a substantial sum for a company whose shares were quoted at 38.27, up 9.00% from a prior close of 35.11, with the session spanning 35.32 to 39.08.

The dilution arithmetic is worth walking through as an illustration, not as a reported term sheet. At the 38.27 level where the stock last traded, $350 million of new equity would correspond to roughly 9.1 million shares — a figure derived purely by dividing the offering size by the current quote, and one that would change with any discount to market, any underwriter option, or any use of convertible or pre-funded structures. The company has not detailed pricing or structure in the material available, so treat that share count as a sizing exercise rather than a forecast.

What the market reaction does tell you is how investors read the trade-off. A 9.00% gain on the day a raise is announced is not the typical response to dilution. It generally means one of two things: either the size of the raise buys enough runway to remove financing risk from the story entirely, or investors read the willingness of buyers to absorb $350 million as a vote of confidence in a near-term catalyst. Raises priced into strength tend to be cheaper for existing holders than raises forced by a cash cliff, and the tape suggests this one falls in the first camp.

Two funding models, one afternoon

Set side by side, the day's two headline items map the financing hierarchy in biotech with unusual clarity.

• Partner capital is the cheapest money a development-stage company can get, because it costs no equity. It is also the least reliable — a large pharma can reprioritize its portfolio without reference to its partner's balance sheet, and there is no appeal.
• Public equity is always available at some price, but the price is set by the market's current mood. For a company trading below a dollar, that price can be prohibitive; for one trading in the high thirties after a 9.00% move, it can be the best deal on the table.
• Timing decides which door is open. Amylyx went to the market on a day it could set terms. TScan lost a partner on a day its stock was already at 0.78.

The Endpoints roundup carrying both items also flagged developments at BioArctic, Enveda, Georgiamune, Kynexis, Tolerance Bio and Network Bio — a reminder that the funding and partnership churn is running across the sector, not just at these two names.

What to watch from here

For TScan, the immediate questions are procedural and financial. When does the termination take legal effect, and does the company regain full rights to any programs that ran through the collaboration? How much research funding was embedded in the arrangement, and what does cash runway look like without it? Reclaimed rights can be an asset — a wholly owned program is worth more per unit of success than a partnered one — but only for a company that can afford to advance it alone.

For Amylyx, the tests are pricing and use of proceeds. Where the offering clears relative to the 38.27 last trade will show how much of the day's enthusiasm was real demand versus positioning, and the disclosed use of proceeds will tell investors whether $350 million is being raised to fund a specific program through a defined milestone or to build a general cushion.

For Amgen shareholders, the read-through is narrower. A terminated discovery partnership says something about internal prioritization and very little about the earnings power of a company trading at 438.43. The more useful signal is directional: when large-cap pharma tightens its external research spending, small-cap partners bear the consequence, and the equity market is the only backstop left.

Key facts

• TCRX: 0.78, down 5.91% (prev close 0.82) as of 17:41 GMT, Aug. 19, 2026
• AMLX: 38.27, up 9.00% (prev close 35.11) as of 17:41 GMT, Aug. 19, 2026
• AMGN: 438.43, up 3.09% (prev close 425.28) as of 17:41 GMT, Aug. 19, 2026
• Amylyx offering: $350 million disclosed

Frequently asked questions

What did Amgen do with its TScan partnership?

Amgen is terminating its partnership with TScan Therapeutics, a Waltham, Massachusetts-based developer of T cell therapies. TScan itself disclosed the termination. The specific financial terms being lost — upfront payments already received, remaining milestones, and ongoing research funding — were not detailed in the disclosure, leaving investors to price an unquantified gap in TScan's funding plan.

How did TScan shares react?

TCRX traded at 0.78, down 5.91% from a prior close of 0.82, with a session range of 0.77 to 0.82, as of 17:41 GMT on Aug. 19, 2026. The sub-dollar quote indicates the market was already assigning limited value to the pipeline before the termination, which narrows the company's practical financing options going forward.

How large is the Amylyx offering and how did the stock respond?

Amylyx disclosed a $350 million offering. Rather than falling on dilution, AMLX rose 9.00% to 38.27 from a prior close of 35.11, trading between 35.32 and 39.08 on the day. A positive reaction to a raise typically signals that investors view the added runway, or the demand for the paper, as outweighing the dilution.

How much dilution would $350 million imply for Amylyx?

As an illustration only, $350 million divided by the 38.27 last trade equates to roughly 9.1 million shares. This is a sizing exercise, not a reported term. Actual dilution depends on any discount to market, underwriter overallotment options, and whether the deal uses common stock, convertibles or pre-funded warrants — none of which have been detailed.

Does the termination matter for Amgen's financials?

Not materially. A single discovery-stage research collaboration is immaterial to a company of Amgen's size. AMGN traded at 438.43, up 3.09% from a prior close of 425.28, on a mixed session for the broader market. Large pharmas routinely prune external research commitments as they reprioritize portfolios, and investors generally treat such decisions as housekeeping.

Which other companies featured in the same industry roundup?

The Endpoints News roundup that carried the Amgen-TScan termination and the Amylyx offering also flagged developments at BioArctic, Enveda, Georgiamune, Kynexis, Tolerance Bio and Network Bio. No financial details for those items were included in the summary, but the breadth of names underlines how active partnership and financing churn is across the biotech sector.

Sources

• Amgen cans its TScan partnership; Amylyx reveals $350M offering — Endpoints News

Photo: https://kaboompics.com/ · Pexels Licence — source